Literature DB >> 22024254

Paget's disease of bone.

Tim Cundy1, Ian R Reid.   

Abstract

OBJECTIVES: To review recent advance in understanding the causation and management of Paget's disease. DESIGN AND METHODS: We review recent publications concerning the aetiology of the disease and the use of biochemical markers of bone turnover in diagnosis and treatment.
RESULTS: Epidemiologic studies suggest that Paget's disease is decreasing in prevalence and severity (implying that environmental factors are important) but there is also strong evidence of a genetic predisposition particularly through the SQSTM1 gene. Genome-wide association studies have identified polymorphisms at several other loci that are associated with the disease. Plasma alkaline phosphatase activity (ALP) is widely used, but less helpful in patients with disease of limited extent. Of the newer markers, plasma procollagen-1 N-peptide (PINP) performs best. Treatment with potent bisphosphonates usually produces long-term remission.
CONCLUSIONS: Both genetic and environmental factors appear to be important in the aetiology of Paget's disease. Effective long-term disease suppression can be achieved with bisphosphonate treatment.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22024254     DOI: 10.1016/j.clinbiochem.2011.09.026

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  7 in total

1.  The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis.

Authors:  Samuel D Vasikaran; S A Paul Chubb
Journal:  Endocrine       Date:  2016-02-23       Impact factor: 3.633

Review 2.  Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts.

Authors:  Brendan F Boyce
Journal:  J Bone Miner Res       Date:  2013-04       Impact factor: 6.741

3.  Periostin and sclerostin levels in juvenile Paget's disease.

Authors:  Stergios A Polyzos; Polyzois Makras; Athanasios D Anastasilakis; Gesthimani Mintziori; Marina Kita; Athanasios Papatheodorou; Panagiotis Kokkoris; Evangelos Terpos
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

Review 4.  Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?

Authors:  Xiao-Long Xu; Wen-Long Gou; Ai-Yuan Wang; Yu Wang; Quan-Yi Guo; Qiang Lu; Shi-Bi Lu; Jiang Peng
Journal:  J Transl Med       Date:  2013-12-11       Impact factor: 5.531

5.  An unusual presentation of metastatic bone disease in a subject with Paget's disease of bone.

Authors:  Shrinath Shetty; Sahana Shetty; Annie Jennifer Prabhu; Nitin Kapoor; Julie Hepzibah; Thomas Vizhalil Paul
Journal:  J Family Med Prim Care       Date:  2016 Apr-Jun

6.  Clinical Characteristics and Pathogenic Gene Identification in Chinese Patients With Paget's Disease of Bone.

Authors:  Xiaohui Tao; Li Liu; Xingguang Yang; Zhe Wei; Zhongzhong Chen; Ge Zhang; Zhenlin Zhang; Hua Yue
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-09       Impact factor: 5.555

7.  Intravenous Zoledronate for a Patient with Paget's Disease.

Authors:  Ki-Choul Kim
Journal:  J Bone Metab       Date:  2014-08-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.